Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. (HOOK) has described itself as a clinical-stage biopharmaceutical company developing next generation immunotherapeutics based on a proprietary arenavirus platform. Its news flow has highlighted programs in oncology and serious infectious diseases, including product candidates targeting HPV16-positive cancers, KRAS mutated cancers, and viral infections such as hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
Company press releases provide detailed updates on its collaboration and license agreement with Gilead Sciences, Inc. For example, HOOKIPA has reported on the HB-400 program in clinical development for HBV and the HB-500 program, a next-generation therapeutic vaccine being evaluated as a potential component of a curative regimen for HIV. News items have described clinical milestones such as enrollment completion in a Phase 1b trial of HB-500, including trial design elements and the intended role of HB-500 in a combination strategy for a potential functional cure of HIV.
HOOKIPA’s news coverage has also included significant corporate and strategic developments. In early 2025, the company issued multiple announcements related to a potential all-share combination with Poolbeg Pharma plc and associated U.K. Takeover Code disclosure requirements, followed by a Rule 2.8 statement that it did not intend to make an offer under Rule 2.7 of the Code. Subsequent releases detailed an asset purchase agreement with Gilead for HOOKIPA’s HB-400 program assets and certain HB-500 assets, and explained how this transaction related to the company’s long-term prospects and strategies.
Later announcements document HOOKIPA’s intention to voluntarily delist its common stock from the Nasdaq Capital Market, deregister its common stock under the Securities Exchange Act of 1934, and seek stockholder approval for dissolution and liquidation. Investors using this news page can review the sequence of clinical updates, collaboration news, U.K. takeover-related disclosures, and corporate actions such as the asset sale to Gilead, the special meeting of stockholders, and the steps toward delisting and deregistration. This provides a consolidated view of both scientific progress and material corporate events affecting HOOKIPA and the HOOK symbol.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has announced that a Trial in Progress poster detailing its ongoing Phase 1/2 study of HB-300 for metastatic castration-resistant prostate cancer has been accepted for presentation at the ASCO Annual Meeting from June 2-6, 2023. The presentation will provide insights into HB-300, a novel immunotherapy utilizing an arenavirus platform, aimed at enhancing immune response specifically against prostate cancer. The details of the presentation include an abstract and poster session scheduled for June 3, 2023. HB-300 aims to elicit robust T cell responses and has shown potential in preclinical studies. The full abstract will be available on May 25, 2023, at 5:00 pm ET.
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a biopharmaceutical company specializing in immunotherapies, announced its participation in investor meetings at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 25-26, 2023. This event highlights HOOKIPA's commitment to advancing its proprietary arenavirus platform aimed at fighting serious diseases.
HOOKIPA is focused on developing therapies that enhance T cell responses to combat various cancers, including Human Papillomavirus 16-positive cancers and prostate cancers. Additionally, the company collaborates with Roche on treatments for KRAS-mutated cancers and aims to create functional cures for HBV and HIV alongside Gilead.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced the granting of non-statutory options for 50,000 shares of Common Stock to a new employee. This decision, approved by the Compensation Committee, is in line with Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee's acceptance of employment. The exercise price is set at $1.00 per share, with a ten-year term and a vesting schedule that includes 25% vesting on the one-year anniversary and the remainder vesting quarterly over three years. HOOKIPA is a biopharmaceutical company focusing on immunotherapies developed from its proprietary arenavirus platform, targeting various cancers and collaborating with Roche and Gilead for future treatments.
HOOKIPA Pharma reported financial results and corporate updates for 2022, highlighting substantial progress in developing immunotherapeutics. The company strengthened its cash position to $113.4 million as of December 31, 2022, with an additional $15.0 million from collaboration milestones in early 2023. HOOKIPA's lead candidate, HB-200, advanced to Phase 2 trials in head and neck cancers, while its prostate cancer program, HB-300, is open for enrollment. The KRAS program (HB-700) achieved its first milestone payment from Roche in February 2023. Revenue decreased to $14.2 million in 2022, down from $18.4 million in 2021, primarily due to lower reimbursements from the Gilead collaboration.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced the appointment of Terry Coelho to its Board of Directors effective April 3, 2023. With over 35 years of experience, including roles in finance and business development at CinCor Pharma and Novartis, Coelho is expected to strengthen HOOKIPA's leadership as it advances its immunotherapeutic pipeline targeting oncology and infectious diseases. CEO Joern Aldag emphasized her strategic insights will be valuable for the company’s ongoing clinical programs. HOOKIPA is known for its proprietary arenavirus platform aimed at developing novel therapeutics for serious diseases.